With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines.
Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle™ platform as key components of a wider industry shift toward scalable nanotechnology-driven drug delivery and AI-enhanced biomedical infrastructure. The company’s approach centers on leveraging platform technologies that may serve multiple therapeutic applications across oncology and rare disease markets rather than depending on a solitary drug candidate. Oncotelic is among several companies, including CytoDyn Inc. (OTCQB: CYDY), Revolution Medicines Inc. (NASDAQ: RVMD), Moderna Inc. (NASDAQ: MRNA) and Sarepta Therapeutics Inc. (NASDAQ: SRPT), that are developing scalable biotechnology platforms designed to support multiple therapeutic programs across diverse disease areas, distinguishing them from traditional single-asset-focused biotechs.
The drug-delivery market, according to industry analysts, is projected to approach $410 billion, driven by the need for improved formulations of existing drugs and the development of novel delivery mechanisms. Platform biotechs, which build technology that can be applied to multiple drugs, are seen as more resilient and scalable compared to companies reliant on a single product. This model reduces risk and allows for more efficient use of research and development capital.
Oncotelic's Deciparticle™ platform, for instance, is a nanotechnology-based drug delivery system designed to enhance the therapeutic index of cancer drugs. The platform aims to improve drug solubility, stability, and targeted delivery, potentially reducing side effects and improving patient outcomes. The company's Sapu003 program is a lead candidate utilizing this technology for the treatment of pancreatic cancer and other solid tumors.
The trend toward platform-based biotechs is also attracting investor attention because these companies can leverage their technology across multiple indications, creating a pipeline of opportunities without starting from scratch for each new drug. This approach is particularly valuable in oncology, where drug resistance and tumor heterogeneity often limit the effectiveness of single-agent therapies.
As the drug-delivery market expands, companies with robust platform technologies are well-positioned to capture market share by offering improved versions of existing drugs or enabling the development of new therapies that were previously impractical due to delivery challenges. The focus on nanotechnology and AI-enhanced design further underscores the industry's move toward precision medicine and personalized treatment approaches.
